Results 61 to 70 of about 22,784 (283)

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3 [PDF]

, 2018
Aims To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs ...
Brito-Sanfiel, Miguel, Buzzetti, Raffaella, Chevalier, Soazig, Lavalle-Gonzalez, Fernando, Merino-Trigo, Ana, Pettus, Jeremy Hodson, Stella, Peter, Yale, Jean-François   +7 more
core   +4 more sources

Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease [PDF]

Vascular Pharmacology, 2017
Dipeptidyl peptidase IV (DPP-IV) has been revealed as an adipokine with potential relevance in cardiovascular disease (CVD), while clinically used DPP-IV inhibitors have demonstrated beneficial cardiovascular effects in several experimental studies. Perivascular adipose tissue (PVAT) is a unique adipose tissue depot in close anatomical proximity and ...
Akoumianakis, I, Antoniades, C
openaire   +3 more sources

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review

Diabetology & Metabolic Syndrome
Background Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type ...
L. M. Pechmann, F. I. Pinheiro, V. F. C. Andrade, C. A. Moreira   +3 more
doaj   +1 more source

Acute Kidney Injury Associated with Linagliptin

Case Reports in Endocrinology, 2016
Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first
Deepak K. Nandikanti, Elvira O. Gosmanova, Aidar R. Gosmanov   +2 more
doaj   +1 more source

Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients [PDF]

Diabetes & Metabolism Journal
Background We investigated the long-term efficacy and safety of initial triple therapy using metformin, a dipeptidyl peptidase-4 inhibitor, and a sodium-glucose cotransporter-2 inhibitor, in patients with type 2 diabetes mellitus. Methods We enrolled 170
Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim   +3 more
doaj   +1 more source

Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and in vitro biological evaluation

Acta Pharmaceutica, 2021
Diabetes mellitus is a chronic illness that needs persistent medical attention and continuous patient self-management to avoid acute complications. Dipeptidyl peptidase-IV (DPP-IV) inhibitors minimize glucagon and blood glucose levels by increasing the ...
Khalaf Reema Abu, Alwarafi Ebtisam, Sabbah Dima   +2 more
doaj   +1 more source

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease

Arthritis Care &Research, Accepted Article.
Objectives Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies. To help patients and providers in the decision‐making process, we developed
Anahita Deboo, Robert Fox, Katherine M. Hammitt, Julie Frantsve‐Hawley, Matthew C. Baker, Stamatina Danielides, Eduardo De Sousa, Brent P. Goodman, Jennifer K. King, Steven Mandel, Ghaith Noaiseh, Pantelis P. Pavlakis, George Sarka, R. Hal Scofield, Arun Varadhachary, Daniel J. Wallace, Matt Makara, Nancy Carteron, Steven Carsons, In collaboration with the Consensus Expert Panel (CEP) members   +19 more
wiley   +1 more source

The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. [PDF]

, 2013
The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively ...
Chakraborty, Sandeep, Dandekar, Abhaya M, Dutta, Mouparna, Ghosh, Anindya S, Goñi, Félix M, Oda, Masataka, Rao, Basuthkar J, Rendón-Ramírez, Adela, Venkatramani, Ravindra, Ásgeirsson, Bjarni   +9 more
core  

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease ...
Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park   +3 more
doaj   +1 more source

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity

Frontiers in Endocrinology, 2022
Type 2 diabetes mellitus is a metabolic disorder resulting from impaired insulin secretion and resistance. Dipeptidyl peptidase (DPP)-IV is an enzyme known to trigger the catalysis of insulinotropic hormones, further abating the endogenous insulin levels
Srishti Chhabria, Srishti Chhabria, Shivangi Mathur, Shivangi Mathur, Sebastian Vadakan, Sebastian Vadakan, Dipak Kumar Sahoo, Pragnyashree Mishra, Biswaranjan Paital   +8 more
doaj   +1 more source